Business Context and Reporting Period
This Form 8-K, filed on January 25, 2021, by Crane Co. (NYSE: CR), reports the results of operations for the quarter ended December 31, 2020. The filing primarily details significant updates regarding the company's asbestos liability, including claim activity, incurred costs, cash payments, and actuarial liability estimates.
Key Financial Metrics: Asbestos Liability and Costs
The filing provides detailed financial data specific to asbestos-related claims and costs for the years ended December 31, 2020, 2019, and 2018. General revenue, profit, and cash flow metrics for the quarter are referenced in an attached press release (Exhibit 99.1) but are not detailed in this text.
| Asbestos Metric (in millions) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Settlement/Indemnity Costs Incurred | $35.3 | $45.5 | $63.0 |
| Defense Costs Incurred | $15.6 | $20.7 | $25.8 |
| Total Costs Incurred | $50.9 | $66.2 | $88.8 |
| Settlement/Indemnity Payments | $24.7 | $38.9 | $61.5 |
| Defense Payments | $16.7 | $21.4 | $26.5 |
| Insurance Receipts | ($10.3) | ($18.8) | ($24.1) |
| Pre-tax Cash Payments (Net) | $31.1 | $41.5 | $63.9 |
Liability and Asset Balances (as of Dec 31, 2020):
- Total Estimated Asbestos Liability: $670 million (down from $712 million in 2019).
- Current Portion of Liability: $66.5 million.
- Probable Insurance Recovery Asset: $87 million (down from $98 million in 2019).
- Pending Claims: 29,138 (including approx. 18,000 in New York, of which 16,000 are inactive non-malignancy claims).
Material Changes Versus Prior Period
- Cost Reductions: Total asbestos costs incurred decreased by 23% to $50.9 million in 2020 compared to $66.2 million in 2019. Net cash payments decreased by 25% to $31.1 million.
- Impact of Pandemic: Management attributes the reduction in 2020 activity to court closures and significantly reduced trial-related activity due to the COVID-19 pandemic.
- Liability Adjustment: The total recorded liability decreased from $712 million (2019) to $670 million (2020). Management determined no change to the liability estimate was warranted for the period ended December 31, 2020, based on actual experience approximating assumptions.
- Claim Volume: Ending pending claims increased slightly to 29,138 from 29,056 in 2019, driven by 2,620 new claims offset by 2,538 settlements and dismissals.
Outlook, Risks, and Contingencies
Outlook: Management expects tort system activity to return to a more normal pace in the second half of 2021, assuming a successful implementation of a COVID-19 vaccine program. Cash payments are expected to continue for years past the 2059 forecast endpoint due to the lag between filing and resolution.
Risks and Uncertainties:
- Estimation Uncertainty: The liability estimate is subject to significant uncertainties regarding future claim volume, severity, and defense costs. Trends in new mesothelioma claims, average settlement costs, dismissal rates, and defense costs are the primary drivers.
- Legal Precedents: Significant adverse verdicts that withstand appeal or changes in case law could materially alter the liability estimate.
- Insurance Recovery: The estimated insurance recovery asset ($87 million) depends on the financial viability of insurers and the interpretation of policy terms. Actual reimbursements may vary.
- Legislative Changes: Federal legislation or structured settlement transactions could impact the liability dynamics.
Unusual Items: The filing details several historical verdicts (Nelson, DeLisle, Poage, Coulbourn) that were either settled or reversed on appeal, illustrating the volatility of asbestos litigation outcomes.
Investor Verification Checklist
- Quarterly Earnings: Verify the specific revenue, net income, and cash flow figures for Q4 2020 in the attached Exhibit 99.1 (Earnings Press Release), as they are not detailed in this 8-K text.
- Liability Assumptions: Review the actuarial assumptions regarding the number of future mesothelioma claims and average settlement costs to understand the $670 million liability reserve.
- Insurance Agreements: Confirm the status of the two remaining solvent excess insurers with whom coverage-in-place agreements have not yet been finalized.
- Cash Flow Impact: Monitor the lag between incurred costs and cash payments, noting that net cash payments ($31.1M) were significantly lower than incurred costs ($50.9M) in 2020.
- Legal Developments: Track any new appellate rulings or legislative changes in key jurisdictions (e.g., New York, Pennsylvania, Florida) that could alter the "Dummitt" precedent or dismissal rates.